![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright © 2005, Cold Spring Harbor Laboratory Press Rad51-dependent DNA structures accumulate at damaged replication forks in sgs1 mutants defective in the yeast ortholog of BLM RecQ helicase 1F.I.R.C. Institute of Molecular Oncology Foundation, 20141, Milan, Italy and Dipartimento di Scienze Biomolecolari e Biotecnologie, University of Milan, Milan, Italy; 2Rosenstiel Center and Department of Biology, Brandeis University, Waltham, Massachusetts, USA 3These authors contributed equally to this work. 4Present address: Institute of Cell Biology, ETH Hönggerberg, CH-8093 Zürich, Switzerland. 5Corresponding author. E-MAIL giordano.liberi/at/ifom-ieo-campus.it; FAX 39-02-574303231. Received August 21, 2004; Accepted December 3, 2004. This article has been cited by other articles in PMC.Abstract S-phase cells overcome chromosome lesions through replication-coupled recombination processes that seem to be assisted by recombination-dependent DNA structures and/or replication-related sister chromatid junctions. RecQ helicases, including yeast Sgs1 and human BLM, have been implicated in both replication and recombination and protect genome integrity by preventing unscheduled mitotic recombination events. We have studied the RecQ helicase-mediated mechanisms controlling genome stability by analyzing replication forks encountering a damaged template in sgs1 cells. We show that, in sgs1 mutants, recombination-dependent cruciform structures accumulate at damaged forks. Their accumulation requires Rad51 protein, is counteracted by Srs2 DNA helicase, and does not prevent fork movement. Sgs1, but not Srs2, promotes resolution of these recombination intermediates. A functional Rad53 checkpoint kinase that is known to protect the integrity of the sister chromatid junctions is required for the accumulation of recombination intermediates in sgs1 mutants. Finally, top3 and top3 sgs1 mutants accumulate the same structures as sgs1 cells. We suggest that, in sgs1 cells, the unscheduled accumulation of Rad51-dependent cruciform structures at damaged forks result from defective maturation of recombination-dependent intermediates that originate from the replication-related sister chromatid junctions. Our findings might contribute to explaining some of the recombination defects of BLM cells. Keywords: Sgs1, RecQ helicases, DNA replication, recombination, checkpoint, Srs2 Homologous recombination is required to repair chromosomal lesions, to assist DNA synthesis, to provide genetic variation, or even to regulate gene expression (Pâques and Haber 1999; Cox 2001; West 2003). In particular, cells experiencing DNA damage while replicating the chromosomes need to couple recombination to replication to overcome the DNA lesions on the template (Kogoma 1997; Pâques and Haber 1999; Foiani et al. 2000; Rhind and Russell 2000). Break-induced replication (BIR) (Signon et al. 2001; Davis and Symington 2004) and template switching (Higgins et al. 1976) may represent possible options for the cell to counteract the dangerous consequences of intra-S DNA damage. Although the genetic requirements of BIR have been defined, the mechanisms and the factors required to promote template switching are still unknown. However, recombination can also be a source of DNA damage as unscheduled recombination events may contribute to genome instability and tumorigenesis (Flores-Rozas and Kolodner 2000). This is the case in the Bloom and Werner cancer-prone syndromes, resulting from mutations in the BLM and WRN genes, respectively, that exhibit enhanced genome instability due to hyperactivation of certain recombination processes. These genes have been implicated in homologous recombination and belong to the highly conserved RecQ DNA helicase gene family (Shen and Loeb 2001; Hickson 2003; Khakhar et al. 2003). In vitro studies have demonstrated that the RecQ DNA helicases are able to separate the complementary DNA strands with 3′-to-5′ polarity in a ATP-dependent manner, but also disrupt a variety of DNA structures, including Holliday junctions (HJs), through a branch migration-like activity (Shen and Loeb 2001; Hickson 2003; Khakhar et al. 2003). HJs are cruciform structures that represent key intermediates in DNA recombination. HJs and HJ-like intermediates have been suggested to arise also during DNA replication, most notably at the rDNA locus (Zou and Rothstein 1997), in the presence of a damaged template (Kowalczykowski 2000), as a result of fork regression (Inmann 1984; Michel et al. 2001; Sogo et al. 2002), or when BIR is occurring (Pâques and Haber 1999). Some of these events seem to represent pathological situations rather than physiological options as in the case of reversed forks that accumulate in response to replication blocks in the absence of a functional checkpoint but not in wild-type cells (Lopes et al. 2001; Sogo et al. 2002). HJ formation can be promoted by the presence of gaps/nicks on DNA and double-strand breaks (DBS) (Heyer et al. 2003) or even from the processing of hemicatenane structures (Schwacha and Kleckner 1995; Lopes et al. 2003). It has been recently shown that four-way sister chromatid junctions (SCJs), resembling hemicatenanes, form at origins of replication during S phase (Lopes et al. 2003). These structures are able to branch migrate behind moving replication forks and have been suggested to assist sister chromatid-mediated recombination and replication bypass processes and, in particular, template switching (Lopes et al. 2003). Although SCJ formation is not influenced by DNA damage and does not depend on homologous recombination proteins, these structures can be converted into HJ-like molecules: This is the case in checkpoint mutants where SCJs seem to contribute to the formation of reversed forks (Lopes et al. 2003) due to a defective replisome-fork association (Lucca et al. 2004). Further, the SCJ/hemicatenane structure could, in theory, result in double HJs or pseudo double HJs (Schwacha and Kleckner 1995; Lopes et al. 2003), while the opposite transition can be promoted by collapsing together two HJs, thus leading to the formation of hemicatenanes (Carr 2002; Heyer et al. 2003; Ira et al. 2003). Mutations in the Saccharomyces cerevisiae SGS1 gene, encoding the only RecQ homolog, cause gross chromosomal rearrangements (Myung et al. 2001) and confer a hyper-recombination phenotype (Gangloff et al. 1994; Watt et al. 1996). The absence of Sgs1 also causes an increase in both mitotic (Ira et al. 2003) and meiotic (Rockmill et al. 2003) recombination. Interestingly, a dramatic stimulation of both sister chromatid exchanges (SCE) and interchromosomal recombination has been observed in human cells carrying genetic defects in the Bloom's syndrome gene (German 1993; Hickson 2003). Altogether, these observations have contributed to the hypothesis that RecQ helicases may be required to prevent unscheduled recombinogenic events (Hickson 2003). However, it should be pointed out that the recombination phenotype of RecQ defective cells seem to be more complex: In fact, the WRN protein is needed to generate viable mitotic recombinants in unperturbed conditions (Prince et al. 2001) and sgs1 mutants are defective in DNA damage-induced heteroallelic recombination (Gangloff et al. 2000; Onoda et al. 2001), suggesting a positive role for RecQ DNA helicases in promoting recombination in certain contexts. Accordingly, genetic evidence and in vitro studies have implicated RecQ helicases not only in preventing the accumulation of recombination intermediates but also in promoting their resolution (Harmon and Kowalczykowski 1998; Fabre et al. 2002; Ira et al. 2003). In particular, a role for Sgs1 in contributing to the maturation of recombination structures is in agreement with the findings that the detrimental effect of homologous recombination in top3 mutants depends on a functional SGS1 gene (Gangloff et al. 1999; Shor et al. 2002) and that Sgs1 physically interacts with the recombination protein Rad51 (Wu et al. 2002). Further, genetic and physical interactions between the type I topoisomerase Top3 and Sgs1 have been described (Gangloff et al. 1994; Bennet et al. 2000; Fricke et al. 2001). RecQ helicases, in combination with Top3, have been suggested to play a role in resolving double HJs through formation of hemicatenanes (Carr 2002; Heyer et al. 2003). Recent observations have indeed established that both Top3 and Sgs1 are required to prevent mitotic crossovers by processing and resolving double HJs generated in response to DSB formation (Ira et al. 2003). Similar conclusions have been obtained by in vitro studies using Blm and TopIIIα proteins, demonstrating that this complex dissolves double HJs avoiding crossovers outcome (Wu and Hickson 2003). Sgs1 is functionally related to Srs2, another 3′-to-5′ DNA helicase (Rong and Klein 1993) that is phosphorylated in response to DNA damage though a mechanism dependent on Cdk1 and on a functional checkpoint (Liberi et al. 2000). SRS2 and SGS1 seem to have both unique and partially overlapping functions. Extensive genetic data have shown that inactivation of both Sgs1 and Srs2 causes a near lethal phenotype that can be rescued by inhibiting homologous recombination, thus suggesting that Sgs1 and Srs2 counteract toxic recombination events (Gangloff et al. 2000; Klein 2001; McVey et al. 2001), possibly through distinct mechanisms (Fabre et al. 2002). It has been suggested that these lethal events may arise spontaneously during DNA replication, rather than in response to DSB formation (Fabre et al. 2002). Moreover, deletions of either gene show a number of synthetic lethal genetic interactions with other replication-associated mutations (Ooi et al. 2003). Both Srs2 and Sgs1 have been implicated in the intra-S DNA damage checkpoint response (Frei and Gasser 2000; Liberi et al. 2000). Further, Srs2 is specifically required for recovery and adaptation in response to checkpoint-mediated arrest prior to repair of a DSB (Vaze et al. 2002), whereas Sgs1 is also implicated in telomere maintenance (Huang et al. 2001). Interestingly, srs2 mutants exhibit a complex recombination phenotype, since they are prorecombinogenic in some contexts (Pâques and Haber 1997; Hegde and Klein 2000; Ira and Haber 2002; Aylon et al. 2003) but antirecombinogenic in others (Aboussekhra et al. 1989; Rong et al. 1991). In addition, recent in vitro experiments have unmasked a Srs2 translocase activity required to disrupt Rad51 nucleofilament, an early intermediate in HJ formation (Krejci et al. 2003; Veaute et al. 2003). Here we show that sgs1 mutants accumulate cruciform DNA molecules at damaged replication forks without impairing fork progression. The formation of these branched structures requires functional Rad51 and Rad52 proteins and is prevented by Srs2 helicase. We also show that subsequent expression of Sgs1, but not Srs2, is able to promote the resolution of the recombination intermediates at damaged forks. We suggest that Sgs1 and, more generally RecQ helicases, together with Top3 topoisomerase act at damaged replication forks to resolve recombination structures likely resulting from replication-related SCJs. Accordingly, we show that the accumulation of the X-shaped Rad51-dependent intermediates in sgs1 mutants requires a functional Rad53 checkpoint kinase that controls the integrity of the SCJs. Results We have studied the role of Sgs1 in controlling chromosome integrity during unperturbed DNA replication and in response to methyl methane sulfonate (MMS)-induced intra-S DNA damage that causes chromosomal rearrangements in wild-type and, to a greater extent, in sgs1 cells (Myung and Kolodner 2002). Using the neutral-neutral two-dimensional (2D) gel electrophoresis technique (Brewer and Fangman 1987), we have analyzed the quality, progression, and processing of replication forks originating from ARS305 (Fig. 1A
We conclude that, under normal conditions, the quality of replication intermediates is comparable in the two strains, although the kinetics of origin firing is slightly anticipated in sgs1 cells. Wild-type and sgs1 cells were then released from G1 in the presence of MMS (Paulovich and Hartwell 1995). In wild-type cells, bubbles accumulate at ARS305 by 20-60 min, while the maximum accumulation of SCJs occurs at 90 min (Fig. 2A
In MMS-treated sgs1 cells, the kinetics of appearance/disappearance of bubbles and Y molecules at ARS305 and at regions A and B are similar to those shown in wild-type cells (Fig. 2A,B
We conclude that homologous recombination contributes to the accumulation of certain X molecules in MMS-treated sgs1 cells that, at least from the genetic point of view, differ from the intermediates represented by SCJs, although both these X-shaped structures migrate on 2D gels similarly. We will refer to the recombination-dependent X-molecules as rec-Xs. We then tested whether the Srs2 and Sgs1 helicases are able to promote the resolution of the rec-Xs in sgs1 mutants. We treated sgs1 cells for 3 h with MMS to promote the accumulation of rec-Xs and we then overexpressed either Srs2 or Sgs1 helicases using a galactose-inducible promoter. Sgs1, but not Srs2, overexpression causes a reduction in the level of the rec-Xs that, with time, become barely detectable (Fig. 4
The previous results suggest that SCJs and rec-Xs are somehow different, although, in principle, SCJs could be converted into rec-X molecules, perhaps due to an active process mediated by recombination factors. To try to address this issue we took advantage of rad53 mutants in which the SCJs form normally at the origins of replication but progressively degenerate at collapsed replication forks into other intermediates (Lopes et al. 2003). Consequently, a large fraction of the SCJs, with time, are converted into gapped molecules (that cannot be longer visualized as X molecules on 2D gels as they cannot be cut with a restriction enzyme), while a smaller fraction contributes to the formation of a cone signal migrating more diffusely on top of the X spike and representing reversed forks (Lopes et al. 2003; see also Fig. 5A
To ask whether the DNA damage checkpoint was required to maintain rec-X structures, we added caffeine to turn off the checkpoint (Vaze et al. 2002) after the formation of the rec-Xs. Despite the complete inactivation of Rad53 kinase observed already at 30 min after caffeine addition (Fig. 5B This result implies that Rad53 inactivation does not influence the stability of the rec-Xs molecules, thus ruling out the possibility that the disappearance of the rec-Xs structures in sgs1 rad53 mutants is due to their unscheduled resolution or destabilization. Altogether, the results shown in Figure 5 We note that while the purification of the SCJ intermediates and their visualization is greatly limited by their intrinsic instability (Lopes et al. 2003), the X molecules accumulating in a Rad51/Rad52-dependent manner in sgs1 cells are more stable, as they can be efficiently visualized using standard protocols for 2D gel analysis (Supplementary Fig. S2). To gain insights into the nature of the rec-Xs and to address whether they may represent HJs, we treated the DNA preparations before 2D gel analysis with RuvC and T4 Endo VII resolvases that are known to cleave HJs (Lilley and White 2001). We found that even after extensive incubations with either RuvC or T4 Endo VII, the rec-Xs remain stable (Fig. 6A
Discussion We showed that in sgs1 cells, replication forks encountering a damaged template are engaged by homologous recombination pathways that promote the accumulation of X-shaped molecules. This event seems to be specifically amplified by MMS-induced DNA damage, as we failed to detect an accumulation of the same structures either under normal conditions or in response to HU-induced replication blockage. Hence, replication fork stalling per se is not sufficient to promote accumulation of rec-Xs. We note that MMS-induced intra-S DNA damage, although causing a delay in DNA synthesis, does not prevent fork progression. It is possible that the accumulation of the rec-Xs requires transient pausing induced by a damaged template coupled with ongoing DNA synthesis. This might also happen under normal conditions in response to endogenous DNA damage as also suggested by previous reports indicating that Sgs1 is required to prevent recombination in cells that have not been exposed to damaging agents (Gangloff et al. 2000; Klein 2001; McVey et al. 2001) although it would be impossible to detect such rare events by 2D analysis. Once accumulated, these rec-Xs do not affect the progression of the fork. Hence, in sgs1 mutants, the forks do not collapse; rather they are able to proceed at the same rate as in wild-type cells and are capable of restarting DNA synthesis, even during recovery from an HU block (data not shown). Thus the sgs1 defect differs from the one seen in rad53 cells. This is also consistent with the observation that, while MMS-treated rad53 cells exhibit unscheduled firing of late/dormant origins (Shirahige et al. 1998), sgs1 mutants do not (data not shown). sgs1 cells have been implicated upstream in the checkpoint pathway based on the observations that, in response to MMS treatment, they seem to complete replication faster than wild-type cells at least by FACS profile and that Rad53 activation is partially dependent on a functional Sgs1 (Frei and Gasser 2000). Our data indicate that (1) sgs1 cells fire the origins prematurely, but fork progression and the bulk of DNA synthesis in the presence of MMS, at least under our experimental conditions, are not accelerated compared to wild-type cells; (2) sgs1 cells do not exhibit the unscheduled activation of late and dormant origins and the fork collapse typical of rad53 cells; rather, the accumulation of rec-X molecules in sgs1 cells depends on a functional Rad53 kinase; (3) we found that MMS-treated sgs1 mutants accumulate more unphosphorylated Rad53 than wild-type cells (Supplementary Fig. S3). However, this apparent failure to properly activate Rad53 is fully restored in sgs1 rad51 double mutants (Supplementary Fig. S3). A possible interpretation of this last result is that the engagement of replication forks into Rad51-dependent recombination structures in sgs1 mutants might indirectly mask the checkpoint signal, perhaps through the unscheduled formation of Rad51 filaments that would compete with the checkpoint signals represented by RPA-ss-DNA filaments (Zou and Elledge 2003; Lucca et al. 2004). This is also consistent with the observation that HU-treated sgs1 cells that do not exhibit Rad51-dependent structures at the forks activate the Rad53 kinase at the same extent as wild-type cells (Frei and Gasser 2000; data not shown). Based on our observations we conclude that sgs1 cells are proficient in the signal transduction pathway leading to activation of the Rad53 kinase and that the apparent inability to fully elicit a checkpoint response is likely due to the unrestrained recombination events that actively limit the amount of checkpoint signal. We also show that Sgs1, but not Srs2, promotes the resolution of the recombination-dependent structures that accumulate at damaged replication forks. This is also consistent with biochemical and genetic observations that implicate Srs2 specifically in inhibiting the initiation of recombination by dismantling Rad51 nucleofilaments (Chanet et al. 1996; Fabre et al. 2002; Ira et al. 2003; Krejci et al. 2003; Veaute et al. 2003), while RecQ helicases appear to be involved in the maturation of recombination intermediates (Harmon and Kowalczykowski 1998; Bennett et al. 1999; Gangloff et al. 1999; Constantinou et al. 2000; Karow et al. 2000; Fabre et al. 2002; Shor et al. 2002; Wu et al. 2002; Ira et al. 2003; Wu and Hickson 2003). Moreover, whereas MMS-treated srs2 cells do not exhibit accumulation of recombination structures at damaged forks (Fig. 7
We failed to detect accumulation of rec-Xs in MMS-treated wild-type cells (see also Lopes et al. 2003). The simplest explanation is that the coordinated action of Srs2 and Sgs1/Top3 efficiently counteracts the accumulation of such X-shaped molecules at damaged forks by preventing their formation and/or by promoting their turnover, thus precluding their visualization. What is the molecular nature of the rec-Xs? More work will be required to firmly establish the physical nature of these structures. However we can formulate some hypotheses. In general, four-branched molecules migrate on 2D gels in the so-called X spike (Brewer and Fangman 1987). X-shaped structures on 2D gels have been related to HJs (Collins and Newlon 1994; Lockshon et al. 1995; Schwacha and Kleckner 1995; Zou and Rothstein 1997) or to hemicatenanes (Lucas and Hyrien 2000; Lopes et al. 2003; Wellinger et al. 2003). The X-shaped SCJ structure that forms during origin firing, based on its properties, has been related to a hemicatenane molecule in which one strand of a duplex is coiled around one strand of the other duplex (Lopes et al. 2003). Hemicatenanes differ from HJs as there is no base pairing in the coiled region, and their formation does not require homologous recombination. We note that, differently from HJs, SCJs/hemicatenanes are able to branch migrate even in the presence of divalent cations and are resistant to RuvC treatment (Lopes et al. 2003; data not shown). The last two properties are also shared by rec-Xs; however, we show that the rec-Xs can be distinguished from SCJs based on the genetic requirement and the relative stability during purification of replication intermediates. The data presented in Figure 6 in Fig. 9
The mechanism proposed in Figure 9 This model also implies that mutations in factors involved in the formation of SCJs might exhibit recombination defects, although such factors have not been identified yet. Altogether our data provide the first physical evidence that, in RecQ helicase mutants, recombination intermediates accumulate during chromosome replication when forks hit a damaged template. We speculate that the pathological resolution of these structures may contribute to genome instability and hyperecombination that are hallmarks of BLM cells (German 1993; Hickson 2003). Materials and methods Strains and plasmids All the strains used in this study are isogenic derivatives of W303-1A (Thomas and Rothstein 1989). SGS1, SRS2, TOP3, RAD51,and RAD52 deletion strains were constructed using the PCR-based gene disruption strategy already described by Wach et al. (1994). Plasmids pAN8 [GAL-SRS2] and pAN11 [GAL-srs2-K41A] were obtained by placing the SRS2 ORF or srs2-K41A mutated sequence, respectively, under the control of the GAL1 inducible promoter in pYES2 multicopy vector. Plasmid pYES2-SGS1 is described by Mankouri et al. (2002). Growing conditions, cell cycle arrests, and drug treatments Unless otherwise indicated, strains were grown at 28°C in YPD medium containing glucose at 2% w/v. Galactose and raffinose were also used at 2% w/v. Cell synchronization was performed by adding 2 μg/mL α-factor to the cultures and by evaluating the percentage of unbudded cells. The release from α-factor arrest was performed by centrifugation and resuspension of cells in fresh medium. MMS, HU, and caffeine were used at final concentrations of 0.033% v/v, 0.2 M, and 10 mg/mL, respectively. DNA extraction, 2D gel technique, FACS, and protein analysis Purification of DNA intermediates in the presence of CTAB, 2D gel procedure, and quantification analysis of autoradiograms were carried out as already described by Lopes et al. (2001, 2003). FACS analysis was performed using a Beckton Dickinson fluorescence-activated cell analyzer, as described by Liberi et al. (2000). TCA protein extraction, SDS-PAGE, and Western blot procedures have also been already described (Liberi et al. 2000). Rad53, Srs2, and Sgs1 were analyzed using polyclonal antibodies JD47 (kindly provided by J. Diffley, Cancer Research UK, South Mimms, UK), YC-18, and YC-17 (Santa Cruz Biotechnology), respectively. In vitro analysis of X-shaped molecules Following first-dimension gel electrophoresis, the slices of agarose were incubated in branch migration buffer (10 mM TrisHCl at pH 8.0, 50 mM NaCl, 10 mM MgCl2, 0.1 mM EDTA), as described by Panyutin and Hsieh (1994). Agarose lanes were then subjected to second-dimension gel electrophoresis. DNA samples, prepared from MMS-treated wild-type and sgs1 cells, were incubated at 37°C before 2D gel electrophoresis with cleavage enzymes at the following conditions: RuvC (kindly provided by I. Hickson, Cancer Research UK, Oxford, UK) at 100 μg for 20 h in buffer containing 12 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 1 mM DTT, 100 μg/mL BSA; T4 Endo VII (USB Corporation), Mung Bean, and S1 (Amersham) were used at 1000 U for 20 h, 50 U for 1 h, and 40 U for 1 h, respectively, in the manufacturer's recommended reaction buffers. Acknowledgments We thank J. Diffley, F. Fabre, L. Fabiani, I. Hickson, G. Ira, H. Mankouri, C. Newlon, J. Sogo, R. Rothstein, R. Wellinger, L. Wu, M. Whitby, V. Zakian, and all members of our laboratories for reagents, procedures, and helpful discussions. We are particularly grateful to H. Mankouri and I. Hickson for sharing unpublished observations with us. We also thank the Sequenc-ing Facility at IFOM. This work was supported by Associazione Italiana per la Ricerca sul Cancro, European Union, and partially by Telethon grant GGP030412 and Ministero della Salute. J.E.H. is supported by NIH grant GM61766 and I.C. and C.L. are supported by fellowships from Fondazione Italiana per la Ricerca sul Cancro and Fondazione Adriano Buzzati-Traverso, respectively. Notes Supplemental material is available at http://www.genesdev.org. Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.322605. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Microbiol Mol Biol Rev. 1999 Jun; 63(2):349-404.
[Microbiol Mol Biol Rev. 1999]Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8173-80.
[Proc Natl Acad Sci U S A. 2001]Nat Rev Mol Cell Biol. 2003 Jun; 4(6):435-45.
[Nat Rev Mol Cell Biol. 2003]Microbiol Mol Biol Rev. 1997 Jun; 61(2):212-38.
[Microbiol Mol Biol Rev. 1997]Mutat Res. 2000 Jun 30; 451(1-2):187-96.
[Mutat Res. 2000]Trends Biochem Sci. 2000 Apr; 25(4):196-200.
[Trends Biochem Sci. 2000]Mech Ageing Dev. 2001 Jul 15; 122(9):921-44.
[Mech Ageing Dev. 2001]Nat Rev Cancer. 2003 Mar; 3(3):169-78.
[Nat Rev Cancer. 2003]Trends Cell Biol. 2003 Sep; 13(9):493-501.
[Trends Cell Biol. 2003]Mech Ageing Dev. 2001 Jul 15; 122(9):921-44.
[Mech Ageing Dev. 2001]Nat Rev Cancer. 2003 Mar; 3(3):169-78.
[Nat Rev Cancer. 2003]Trends Cell Biol. 2003 Sep; 13(9):493-501.
[Trends Cell Biol. 2003]Cell. 1997 Jul 11; 90(1):87-96.
[Cell. 1997]Trends Biochem Sci. 2000 Apr; 25(4):156-65.
[Trends Biochem Sci. 2000]Mol Cell. 2003 Dec; 12(6):1499-510.
[Mol Cell. 2003]Oncogene. 2004 Feb 12; 23(6):1206-13.
[Oncogene. 2004]Cell. 1995 Dec 1; 83(5):783-91.
[Cell. 1995]DNA Repair (Amst). 2002 Dec 5; 1(12):983-94.
[DNA Repair (Amst). 2002]Trends Biochem Sci. 2003 Oct; 28(10):548-57.
[Trends Biochem Sci. 2003]Nat Genet. 2001 Jan; 27(1):113-6.
[Nat Genet. 2001]Mol Cell Biol. 1994 Dec; 14(12):8391-8.
[Mol Cell Biol. 1994]Genetics. 1996 Nov; 144(3):935-45.
[Genetics. 1996]Cell. 2003 Nov 14; 115(4):401-11.
[Cell. 2003]Curr Biol. 2003 Nov 11; 13(22):1954-62.
[Curr Biol. 2003]Nat Rev Cancer. 2003 Mar; 3(3):169-78.
[Nat Rev Cancer. 2003]Genes Dev. 2001 Apr 15; 15(8):933-8.
[Genes Dev. 2001]Nat Genet. 2000 Jun; 25(2):192-4.
[Nat Genet. 2000]Mol Gen Genet. 2001 Jan; 264(5):702-8.
[Mol Gen Genet. 2001]Genes Dev. 1998 Apr 15; 12(8):1134-44.
[Genes Dev. 1998]EMBO J. 1999 Mar 15; 18(6):1701-11.
[EMBO J. 1999]Genetics. 2002 Oct; 162(2):647-62.
[Genetics. 2002]Mol Cell Biol. 1994 Dec; 14(12):8391-8.
[Mol Cell Biol. 1994]J Biol Chem. 2000 Sep 1; 275(35):26898-905.
[J Biol Chem. 2000]J Biol Chem. 2001 Mar 23; 276(12):8848-55.
[J Biol Chem. 2001]J Biol Chem. 1993 Jan 15; 268(2):1252-9.
[J Biol Chem. 1993]EMBO J. 2000 Sep 15; 19(18):5027-38.
[EMBO J. 2000]Nat Genet. 2000 Jun; 25(2):192-4.
[Nat Genet. 2000]Genetics. 2001 Feb; 157(2):557-65.
[Genetics. 2001]Genetics. 2001 Apr; 157(4):1531-42.
[Genetics. 2001]Mol Cell Biol. 1997 Nov; 17(11):6765-71.
[Mol Cell Biol. 1997]Nucleic Acids Res. 2000 Jul 15; 28(14):2779-83.
[Nucleic Acids Res. 2000]Mol Cell Biol. 2002 Sep; 22(18):6384-92.
[Mol Cell Biol. 2002]Mol Cell Biol. 2003 Feb; 23(4):1403-17.
[Mol Cell Biol. 2003]Nucleic Acids Res. 1989 Sep 25; 17(18):7211-9.
[Nucleic Acids Res. 1989]Proc Natl Acad Sci U S A. 2002 Apr 2; 99(7):4500-7.
[Proc Natl Acad Sci U S A. 2002]Cell. 1987 Nov 6; 51(3):463-71.
[Cell. 1987]Cold Spring Harb Symp Quant Biol. 1993; 58():415-23.
[Cold Spring Harb Symp Quant Biol. 1993]Mol Cell. 2003 Dec; 12(6):1499-510.
[Mol Cell. 2003]Trends Biochem Sci. 1998 Apr; 23(4):131-4.
[Trends Biochem Sci. 1998]Cell. 1995 Sep 8; 82(5):841-7.
[Cell. 1995]Nature. 2001 Aug 2; 412(6846):553-7.
[Nature. 2001]Mol Cell. 2003 Dec; 12(6):1499-510.
[Mol Cell. 2003]Cell. 1994 Jan 14; 76(1):65-75.
[Cell. 1994]Cell. 1995 Jun 16; 81(6):947-55.
[Cell. 1995]Cell. 1995 Dec 1; 83(5):783-91.
[Cell. 1995]Cell. 1997 Jul 11; 90(1):87-96.
[Cell. 1997]Nucleic Acids Res. 2000 May 15; 28(10):2187-93.
[Nucleic Acids Res. 2000]Mol Cell. 2003 Dec; 12(6):1499-510.
[Mol Cell. 2003]Mol Cell. 2002 Aug; 10(2):373-85.
[Mol Cell. 2002]Mol Cell. 2003 Dec; 12(6):1499-510.
[Mol Cell. 2003]Nat Rev Mol Cell Biol. 2001 Jun; 2(6):433-43.
[Nat Rev Mol Cell Biol. 2001]Proc Natl Acad Sci U S A. 1994 Mar 15; 91(6):2021-5.
[Proc Natl Acad Sci U S A. 1994]Nat Genet. 2000 Jun; 25(2):192-4.
[Nat Genet. 2000]Genetics. 2001 Feb; 157(2):557-65.
[Genetics. 2001]Genetics. 2001 Apr; 157(4):1531-42.
[Genetics. 2001]Nature. 1998 Oct 8; 395(6702):618-21.
[Nature. 1998]Genes Dev. 2000 Jan 1; 14(1):81-96.
[Genes Dev. 2000]Science. 2003 Jun 6; 300(5625):1542-8.
[Science. 2003]Oncogene. 2004 Feb 12; 23(6):1206-13.
[Oncogene. 2004]Mol Cell Biol. 1996 Sep; 16(9):4782-9.
[Mol Cell Biol. 1996]Proc Natl Acad Sci U S A. 2002 Dec 24; 99(26):16887-92.
[Proc Natl Acad Sci U S A. 2002]Cell. 2003 Nov 14; 115(4):401-11.
[Cell. 2003]Nature. 2003 May 15; 423(6937):305-9.
[Nature. 2003]Nature. 2003 May 15; 423(6937):309-12.
[Nature. 2003]Mol Cell. 2003 Dec; 12(6):1499-510.
[Mol Cell. 2003]Cell. 1987 Nov 6; 51(3):463-71.
[Cell. 1987]Cell. 1994 Jan 14; 76(1):65-75.
[Cell. 1994]Cell. 1995 Jun 16; 81(6):947-55.
[Cell. 1995]Cell. 1995 Dec 1; 83(5):783-91.
[Cell. 1995]Cell. 1997 Jul 11; 90(1):87-96.
[Cell. 1997]Medicine (Baltimore). 1993 Nov; 72(6):393-406.
[Medicine (Baltimore). 1993]Nat Rev Cancer. 2003 Mar; 3(3):169-78.
[Nat Rev Cancer. 2003]Cell. 1989 Feb 24; 56(4):619-30.
[Cell. 1989]Yeast. 1994 Dec; 10(13):1793-808.
[Yeast. 1994]Nucleic Acids Res. 2002 Mar 1; 30(5):1103-13.
[Nucleic Acids Res. 2002]Nature. 2001 Aug 2; 412(6846):557-61.
[Nature. 2001]Mol Cell. 2003 Dec; 12(6):1499-510.
[Mol Cell. 2003]EMBO J. 2000 Sep 15; 19(18):5027-38.
[EMBO J. 2000]Proc Natl Acad Sci U S A. 1994 Mar 15; 91(6):2021-5.
[Proc Natl Acad Sci U S A. 1994]Cold Spring Harb Symp Quant Biol. 1993; 58():415-23.
[Cold Spring Harb Symp Quant Biol. 1993]